Aim Interest in the quality of economic analyses is increasing in the field of decision-making. Drummond's checklist is a useful tool. This study aimed to use a weighted version of Drummond's checklist together with a consensus of experts to derive a new scoring system to improve the evaluation of economic analyses of tetravalent human papillomavirus (HPV) vaccine as a case study. Methods Drummond's checklist is composed of 35 items divided into 3 sections: study design, data collection and analysis and interpretation of results. To weight the items, a group of experts was asked to attribute a score according to their importance. A bibliographic search of economic evaluations of tetravalent HPV vaccine was performed. Two researchers assessed the quality of selected studies according to the original and weighted checklist.
allocate limited resources (Beutels et al. 2007 ). The introduction of a new technology causes a great mobilisation of resources and, for these reasons, decisions should be supported by high-quality evidence. In several European and extra-European countries, decisions about reimbursement and price of new drugs are taken considering not only safety, efficacy and effectiveness, but also cost-effectiveness. In some countries, such as Australia, Canada, Sweden, Netherlands, Ireland, Norway, Finland, Belgium, Estonia, Latvia and the UK, this economic analysis is compulsory in order to determine the price and reimbursement of new and innovative drugs (Russo 2008) . In other countries, such as Italy, France, Germany and Greece, the inclusion of pharmacoeconomic analysis into price or reimbursement requests is not mandatory (Russo 2008) .
Therefore, the need to control and evaluate the quality of reporting and methods used in pharmacoeconomic analyses is clearly a fundamental issue for public health decisionmakers (Jefferson and Demicheli 2002) . Drummond and Jefferson (1996) and Drummond et al. (1997) published guidelines for the evaluation of the quality of economic analyses both for authors and reviewers on the basis of a qualitative judgement only; the checklist has become one of the most commonly employed in the quality assessment of economic evaluations. Moreover, it has been affirmed that Drummond's checklist is a feasible tool to collect baseline information on the quality of studies, irrespective of the journals which published them (Gerard et al. 2000) . Several reports of quality assessment of economic analyses have been published (Neumann et al. 2000; Siegel et al. 1996; Gerard et al. 1999; Petrou et al. 2000) . Also, the evaluation of the quality of studies is a well-known step in systematic reviews and meta-analyses (Higgins and Green 2008; Centre for Reviews and Dissemination 2009) which are becoming increasingly important to support decision-making. In this context, the need for developing and implementing the use of quality assessment tools in the field of economic evaluation is a priority to enable decision-makers to understand the reliability and robustness of data (La Torre et al. 2006) . Checklists are described as a tool for assessing the quality of studies, even though scoring systems are not generally recommended. In particular, for economic analysis, available scoring systems were judged to be not completely reliable and valid (Thurston et al. 2008) . Several experts advocate the use of weighted items of checklists for the evaluation of economic analyses (Ungar and Santos 2003; GonzalezPerez 2002) . Moreover, currently available scoring systems for assessing the quality of economic analysis are, in same cases, not based on a well-known and commonly shared checklist but on key elements drawn from different checklists (Chiou et al. 2003; Wallace et al. 2002; Ungar and Santos 2003) ; others were developed which gave a full score to items for which an explicit answer was retrievable in the text and half score in the case of an unclear answer in the text (Gonzalez-Perez 2002) . All these systems were judged to be useful for researchers and policy-makers to evaluate the quality of studies, even though they have limitations. We believe that further effort could be made to assign each item more or less weight according to its importance, as noted by Chiou et al. (2003) . With this aim, we chose the most common and well-known checklist nowadays available to try to develop a new scoring system for decision-makers to evaluate the quality of studies and perform stratified and sensitivity analyses in systematic reviews. The novelty of the work is the choice of the most commonly used checklist, the involvement of experts who are not necessarily economists and the attempt to develop a user-friendly weighted scoring system.
The old and newly developed checklists were then used to assess the quality of economic analyses of tetravalent human papillomavirus (HPV) vaccine (against genotypes 6, 11, 16 and 18) . This work derives from a Health Technology Assessment (HTA) project about the tetravalent HPV vaccine (La Torre et al. 2009 ). HTA is a multidisciplinary approach to evaluate the introduction or the implementation of technology that takes into account epidemiological, clinical, technical, economic, organisational, social, legal and ethical topics; HPV vaccine was the first which aimed to prevent an oncological disease. In carrying out HTA on tetravalent HPV vaccine, published economic analyses of tetravalent vaccine were assessed in order to evaluate their quality and to summarise data about its cost-effectiveness.
The specific aims of this work were: (1) to attribute a weight to the items of the original Drummond's checklist which was employed to assess the quality of studies and (2) to apply the original and the weighted Drummond's checklist to the economic analyses of tetravalent HPV vaccine as a case study of the application of the weighted checklist.
Methods

Checklist weighting process
The British Medical Journal (BMJ) referees' checklist, proposed by Drummond and Jefferson (1996) and specific for economic evaluation, was chosen as the quality assessment tool for the study. It is composed of 35 items divided into 3 sections: study design (7 items), data collection (14 items) and analysis and interpretation of results (14 items). Each item could be completely satisfied (yes) or not (no) or not clearly reported (not clear) or not applicable (not appropriate).
To accomplish our first objective, that of attributing a weight to each item of the checklist, an opportunistic sample of experts (consensus) in health economics, epidemiology and public health was selected among key professionals involved in economic evaluations in Italy. The opportunistic sample of experts was asked, by e-mail, to attribute, according to their personal knowledge and experience, a possible score from 1 to 4 to each item of the original Drummond's checklist: Whenever an answer to the first invitation was not obtained, a maximum of two reminders were sent by e-mail.
The median values of weights assigned by the consensus to each item were considered to compute the highest global and section scores.
The Kruskal-Wallis test was applied to assess any difference in weights assigned to each item by the three groups of experts (epidemiologists, health economists and public health experts) involved in weighting. The result of the Kruskal-Wallis test was used to make the decision to combine data from all the experts or to perform a separate analysis according to the experts' backgrounds.
The statistical significant level was set at p=0.05. The statistical analysis was performed using SPSS 12.0 for Windows. . In order to identify other possible studies of interest, the electronic research was supplemented by manual examination of the reference lists of articles found by the PubMed search in order to find all available full and partial economic evaluations of tetravalent HPV vaccine. Economic analyses published only on national reports of technology evaluation were not included in our analysis.
In the selection process, abstracts were first read independently by two researchers (CdW and NN) to identify potentially eligible papers whose full text was retrieved and assessed in order to decide on the final inclusion.
For each selected study, two researchers (CdW and NN) independently assessed the quality according to the original Drummond's checklist. Discrepancies between the two investigators were solved by oral discussion and consensus with a senior investigator (GLT). After this first evaluation, each item was assigned with the median weight attributed by the consensus, if satisfied at the application of the original Drummond's checklist. Finally the global score was computed summing up weights of each item. To compare between studies, global scores were referred, in percentage, to the highest score achievable with the weighted Drummond's checklist.
Results
Checklist weighting process
The consensus of experts selected for the weighting was composed of 25 people; 17 of them agreed to participate (6 health economists, 5 epidemiologists and 6 public health experts). Non-responders were two epidemiologists, two public health experts and four health economists; three refused to join the consensus while the others did not answer the mail invitations. Drummond's checklist with median weights assigned to each item is shown in Table 1 . In the table, median scores given by each group of experts are also reported alongside with p values determined by the Kruskal-Wallis test.
For each section of items the maximum achievable score was as follows:
Study design (7 items):
Maximum global score=26 2. Data collection (14 items):
Maximum global score=45 3. Analysis and interpretation of results (14 items):
Maximum global score=48
Little differences were observed between weights assigned by the three expert groups: none of the 35 items produced a statistically significant difference. The global highest achievable score (Table 1) was thus 119.
Identification of relevant studies
From the literature search (35) and bibliographic lists reviewed (45), 80 potentially eligible studies were retrieved. After titles and abstracts were read, 21 passed to the full-text review. Of 21 papers, 13 were finally included in the analysis (Insinga et al. 2007; Insinga et al. 2008; Chesson et al. 2008; Elbasha et al. 2007; Brisson et al. 2007 ; Bergeron et al. 2008; Ginsberg et al. 2007; Boot et al. 2007; Dasbach et al. 2008; Szucs et al. 2008; Kulasingam et al. 2008; Jit et al. 2008; Mennini et al. 2009 ). All articles which dealt with the economic analysis of bivalent vaccine (against genotypes 16 and 18) were excluded as well as papers in a non-English language. Details about excluded articles are reported in Fig. 1 . Of 13 papers, 12 were cost-effectiveness analyses while 1 ) was a cost of illness analysis based on the FUTURE study, a trial on tetravalent HPV vaccine.
Quality assessment
Considering the original Drummond's checklist, all the studies clearly defined the research objective and question (item 1) and sources of efficacy data (item 8) and reported appropriate conclusions (item 34) giving a satisfactory answer to the research question (item 33). In most studies (about 8-12 of 13) something was stated about the economic importance of the research (item 2), the viewpoint of analysis was clarified and justified (item 3) and comparators and rationale of their choice were clearly described (items 4 and 5). In addition, economic analysis type (item 6), outcomes (item 11), methods to evaluate health status and benefits (item 12), money currency (item 18), model details (item 20), time horizon of analysis (item 22) and discount rate (item 23) were described. Moreover, most studies stated that a sensitivity analysis was performed (item 27) and described ranges of parameter variation (item 29). Most studies compared relevant alternatives in the Fig. 1 Flow chart of the selection process model (item 30) and reported incremental analysis (item 31); the limitations of studies were moreover discussed in most of the works (item 35). The flaws identified in the studies were: the choice of the model was not justified (item 7), details of efficacy sources and of patients on whom data were retrieved were missing (items 9 and 13), resources and costs were not reported separately (16), methods for their computation were not described (item 17) and details of adjustment for inflation or currency conversion (item 19) were not given. Moreover, the choice of model, parameters, discount rate and parameters to vary was not justified (items 21, 24 and 28). Studies were lacking details of statistical analysis (item 26) and results were often reported only in an aggregate way (item 32). For details about each single item see Table 2 .
According to our weighted Drummond's checklist, the median quality score of selected studies was 74 (min. 46, max. 80). The highest score was reached in the study design section; the median score of this part was 19 (min. 12, max. 26) and only one study (Brisson et al. 2007 ) attained the maximum possible score. Good results were achieved also in the analysis and interpretation of results section: the median score was 30 (min. 21, max. 42).
The lowest median score was observed in the data collection (median 22, min. 10, max. 31). Table 3 shows quality assessment results. It can be noted that almost all studies received a quality score over 50% of the highest possible, 119, but none reached 70% of it.
Discussion
The present study deals with Drummond's checklist which is already widely used by authors and reviewers to assess the completeness of economic analysis reporting. Different attempts to assess the quality of reporting have been carried out by different authors. Neumann et al. (2000) published a work about the assessment of 228 cost-utility analyses over the period 1976-1997; they employed a form, developed on the basis of the 'checklist' for reporting reference case cost-utility analyses recommended by the Panel on Cost-Effectiveness in Health and Medicine (Siegel et al. 1996) , other published guidelines and by recommendations and discussions with experts in the field. Collected data ranged from disclosure of funding sources, reporting of the framing of analysis, reporting of costs, preference weights, results and description of key elements in the discussion section. The results revealed that the weakest parts were the definition of study perspective, the provision of a diagram of the model or event pathway, the reporting of the discount rate for both costs and quality-adjusted life years, the definition of the year in which monetary units were valued, the appropriate reporting of incremental cost-effectiveness ratios and the discussion of ethical implications.
Further studies on evaluation of economic analyses were carried out in the 1990s. Gerard et al. (1999) showed incongruent perspectives and serious deficiencies in the estimation of costs, interpretation of results and the use of patients for eliciting utility weights, whereas Petrou et al. (2000) analysed 41 works on antenatal screenings accounting for methodological topics on the basis of Drummond's guideline. The weakest areas were: failure to provide detailed and disaggregated information on reported costs, failure to discount future care costs and the poor use of sensitivity analysis, often applied only to clinical or epidemiological parameters.
Our study adds the weighting of each evaluation item to previous analyses. The assessment of the quality of economic analyses aids informed reading of the current literature and improves homogeneity and reliability of the decision-making process. That is why we chose to use a newly developed and widely used checklist to weight the importance of each item using the opinions of a group of well-known experts in epidemiology, public health and economics who were involved in health economic analyses from different viewpoints and thus representative of all the perspectives in the evaluation of economic analyses. The development of the weighting system was the main goal of our work so that assessment of the quality of economic analyses could be more thorough. It must be underlined that other attempts to weight Drummond's checklist have been reported: Gonzalez-Perez (2002) demonstrated that the development of a weighting system improves discrimination of the quality of studies and of their importance, robustness and correctness.
The present work of weighting found that the most important aspects to be considered in economic analyses are: for study design, the definition/justification of the research question, viewpoint of analysis, alternatives and form of economic evaluation; for data collection, the description of outcomes, model and its parameters, sources of effectiveness data and methods to evaluate health benefits and costs; and for interpretation of results, the identification of the time horizon, discount rate and sensitivity analysis and justification of conclusions.
Most of these elements were identified as main flaws of economic analyses by Drummond and Sculpher (2005) themselves; they also underlined the potential problems arising from indirect comparisons, inappropriate extrapolation beyond the period observed in clinical studies, the excessive use of assumptions rather than data and the selective reporting of findings.
The well-recognised importance of such elements could justify, in our opinion, the development of a scoring system able to assign a different value to single items of already available checklists.
Also it is very interesting to observe that methodological lacks and flaws are not only present in published studies but also in economic evaluations of dossiers sent to institutional bodies for decisions on drug reimbursement or price. This was verified both in Italy and in an international setting (Russo 2008; Hill et al. 2000) . For these reasons, in our opinion, it is important to underline that the introduction of a new technology, such as a vaccine, should be based not only on economic evaluation but on a multidisciplinary assessment, such as HTA which also includes an economic evaluation (La Torre et al. 2007) . The viewpoints of the analysis are clearly stated and justified 9 3 1 0 4
The rationale for choosing the alternative programmes or interventions compared is stated
The alternatives being compared are clearly described 11 1 1 0 6
The form of economic evaluation used is stated 12 0 1 0 7
The choice of form of economic evaluation is justified in relation to the question addressed Our second aim was to apply Drummond's tool, both as checklist and as quality score system, to the economic evaluations of tetravalent HPV vaccine in the context of an HTA project. HPV vaccine is a relatively new topic in the international scenario and in Italy has been introduced, free of charge, for 12-year-old girls; the increasing interest has led in the last 2 years to several publications concerning health economic aspects. It is presumable that the growing interest in economic assessment has been also driven by the need for evidence to support decision-makers. Our review yielded 13 papers on the economic evaluation of tetravalent HPV vaccine: 4 of them were American (2 in the USA, 1 in Canada and 1 in Mexico) whereas 7 were European and 1 Israeli. One study was the economic evaluation of the FUTURE II study, a multicentre randomised clinical trial on tetravalent vaccine.
After assessing the articles for quality, economic evaluations of tetravalent HPV vaccine were found to be of medium quality. The most important quality problems were in "data collection" and "analysis and interpretation of results". For data collection, lack of quality was mainly due to problems about reporting of efficacy, utility, resources and cost sources. On the other hand, analysis and interpretation of results were affected by lack of statistical details, justification of discount rates and sensitivity analysis. It is interesting to observe that these items were assigned the highest weights by the consensus: this means that the quality evaluation performed with the weighted Drummond's checklist led to relatively worse results than the application of the original un-weighted checklist.
Our work does have limitations. First, one of the most important weaknesses is that the weighting of Drummond's checklist items was performed only by a narrow group of experts who were all Italians. This means that our work is not conclusive and further experience of weight attribution nationally and internationally would be desirable. The validation of the system of weights assigned by the consensus of experts should be monitored in order to assess its reliability. Moreover, the scoring system used here cannot reflect the total quality of papers because Drummond's checklist is focused on reporting of results and not on methods used to carry out the analysis. In any case, it may be difficult to standardise some aspects of economic evaluations such as the kind of model to use or the discount rate to apply. For this review of tetravalent HPV vaccine economic analyses, the main weakness is the possible selection bias due to the search strategy. In fact, a lot of studies have been carried out worldwide to investigate the economic implications of this vaccine, and thus it is possible that several studies were not selected. The limited search strategy excluded economic analyses reported only on HTA dossiers and not published in peerreviewed journals available on PubMed. Moreover, studies carried out in Asia or in Africa, as well as in other countries but not written in English, could not be included in the analysis. Alongside selection bias, sponsor bias and publication bias cannot be excluded.
Conclusion
Drummond's checklist could be proposed as a standard reference to evaluate economic analyses and the system of weights could lead to a better quality assessment. This could improve a critical evaluation of the literature. 
